Back to Resources
Market Highlights
- The European ovarian, endometrial, and pan-tumor dMMR cancers market circulated materials mostly in digital format and targeting German physicians.
- AbbVie announced Elahere’s UK MHRA approval as a monotherapy for adult patients with platinum-resistant ovarian cancer with high levels of FRα.
- AstraZeneca featured the efficacy of the Imfinzi/Lynparza combination in pMMR endometrial with the “Sail” campaign. Meanwhile, Lynparza was noted as an effective option for HRD+ advanced ovarian cancer.
- GSK positioned Jemperli as “the only approved immunotherapy + carboplatin-paclitaxel with significant OS benefit” in endometrial carcinoma, and the “Light” campaign was noted. Meanwhile, Zejula’s new tablet was advertised.
- MSD highlighted World Ovarian Cancer Day and featured the efficacy of Keytruda alone or in combination with Lenvima in endometrial carcinoma, supported by the KEYNOTE studies.
- Pharma& featured Rubraca’s approval as first- and second-line maintenance therapy for advanced ovarian cancer. The ATHENA-MONO study demonstrated superior PFS compared to placebo regardless of BRCA or HRD status.
Questions about this SnapShot or other markets?
U.S. MARKETS
Christine Alongi
alongi@dtwresearch.com
GLOBAL MARKETS
Robin Cefalo
cefalo@dtwresearch.com
SOCIAL MEDIA MARKETS
Andrew Carney
carney@dtwresearch.com